Coherus Oncology (CHRS) Receivables (2013 - 2026)

Coherus Oncology has disclosed Receivables across 13 years of filings, most recently posting $22.5 million for Q1 2026.

• Receivables for Q1 2026 came in at $22.5 million, down 63.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.5 million (down 63.95% YoY), and the FY2025 annual result was $18.4 million, down 84.94% from the prior year.
• Receivables came in at $22.5 million for Q1 2026 at Coherus Oncology, up from $18.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $313.6 million in Q2 2024 to a low of $18.4 million in Q4 2025.
• The 5-year median for Receivables is $119.6 million (2025), against an average of $149.8 million.
• Across the five-year window, Receivables soared 180.07% in 2024 and sank 84.94% in 2025, its largest moves.
• Coherus Oncology's Receivables stood at $110.0 million in 2022, then soared by 136.92% to $260.5 million in 2023, then tumbled by 53.04% to $122.3 million in 2024, then tumbled by 84.94% to $18.4 million in 2025, then gained by 22.22% to $22.5 million in 2026.
• The last three Receivables figures came in at $22.5 million (Q1 2026), $18.4 million (Q4 2025), and $250.5 million (Q3 2025), per Business Quant data.